IMS2186
IMS2186 is an anti-choroidal neovascularization (CNV) agent that inhibits angiogenesis upstream of VEGF. IMS2186 can arrest cancer cell cycle in G2/M phase, thus exerting anti-proliferation and anti-angiogenesis effects. IMS2186 has no intraocular toxicity and reduces the amount of eye leakage and diseased cells[1].
Product Specifications
CAS Number
[1031206-36-6]
UNSPSC
12352005
Hazard Statement
H410
Target
VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/ims2186.html
Purity
99.96
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
O=C1/C(COC2=CC=C(C)C=C12)=C/C3=CC=C(OC)C(O)=C3
Molecular Formula
C18H16O4
Molecular Weight
296.32
Precautions
H410
References & Citations
[1]Falkenstein IA, et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res. 2008 Jul;33 (7) :599-609. |[2]DeNiro M, et al. Reversal of retinal vascular changes associated with ocular neovascularization by small molecules: progress toward identifying molecular targets for therapeutic intervention[J]. VASCULAR, 2011, 15: P17.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6131309-01 0.1 mL
FKBP1B (h-FKBP-12, Immunophilin FKBP12.6, 12.6kD FK506-binding Protein, 12.6kD FKBP, FKBP-12.6, Rotamase, FK506-binding Protein 1B, FKBP-1B, Peptidyl-prolyl cis-trans Isomerase FKBP1B, PPIase FKBP1B, FKBP12.6, FKBP1L, FKBP9, OTK4) (AP)
Ask
View Details 
MBS6131309-02 5x 0.1 mL
FKBP1B (h-FKBP-12, Immunophilin FKBP12.6, 12.6kD FK506-binding Protein, 12.6kD FKBP, FKBP-12.6, Rotamase, FK506-binding Protein 1B, FKBP-1B, Peptidyl-prolyl cis-trans Isomerase FKBP1B, PPIase FKBP1B, FKBP12.6, FKBP1L, FKBP9, OTK4) (AP)
Ask
View Details